Issue 1/2001
Content (13 Articles)
Chronic Oral Administration of CI-994: A Phase I Study
Sucharu Prakash, Brenda J. Foster, Mark Meyer, Antoinette Wozniak, Lance K. Heilbrun, Lawrence Flaherty, Mark Zalupski, Louis Radulovic, Manuel Valdivieso, Patricia M. LoRusso
Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia
Francis Giles, Jorge Cortes, Guillermo Garcia-Manero, Stephen Kornblau, Elihu Estey, Monica Kwari, Anthony Murgo, Hagop Kantarjian
A Phase I Study of Vitamin E, 5-Fluorouracil and Leucovorin for Advanced Malignancies
Charles D. Blanke, Michael Stipanov, Jason Morrow, Mace Rothenberg, Rebecca Chinery, Yu Shyr, Robert Coffey, David H. Johnson, Steven D. Leach, R. Daniel Beauchamp
Phase I Study of N1-N11-Diethylnorspermine (DENSPM) Administered TID for 6 Days in Patients with Advanced Malignancies
Richard R. Streiff, John F. Bender
Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11
Toshimichi Miya, Tomoyuki Goya, Hirofumi Fujii, Tomoko Ohtsu, Kuniaki Itoh, Tadahiko Igarashi, Hironobu Minami, Yasutsuna Sasaki
Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma
Shailendra Lakhanpal, Ross C. Donehower, Eric K. Rowinsky
A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study
Steven C. Plaxe, John A. Blessing, Joseph A. Lucci, Jean A. Hurteau
Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma
Won Seog Kim, Myung Min Kim, Hae Jin Choi, Sung-Soo Yoon, Mark Hong Lee, Keunchil Park, Chan H. Park, Won Ki Kang
A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with Chemotherapy
Jonathan E. Dowell, David H. Johnson, John S. Rogers, Yu Shyr, Nancy McCullough, Peggy Krozely, Russell F. DeVore
Toxicity and Response Evaluation of the Interferon Inducer Poly ICLC Administered at Low Dose in Advanced Renal Carcinoma and Relapsed or Refractory Lymphoma: A Report of Two Clinical Trials of the Eastern Cooperative Oncology Group
Bruce J. Giantonio, Howard Hochster, Ronald Blum, Peter H. Wiernik, Gary R. Hudes, John Kirkwood, Donald Trump, Martin M. Oken
Achievement of Complete Remission in Refractory Hodgkin's Disease with Prolonged Infusion of Gemcitabine
Orhan Sezer, Jan Eucker, Christian Jakob, Olaf Kaufmann, Peter Schmid, Kurt Possinger